Correspondence 0001193125-23-210997 from Seres Therapeutics, Inc. (MCRB) (CIK 0001609809) (MCRB)
Seres Therapeutics, Inc. (MCRB) (CIK 0001609809)
Date: Aug. 11, 2023 · CIK: 0001609809 · Accession: 0001193125-23-210997
AI Filing Summary & Sentiment
File numbers found in text: 333-273794
Letter
Seres Therapeutics, Inc.
200 Sidney Street – 4th Floor
Cambridge, MA 02139
August 11, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Seres Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 8, 2023
File No. 333-273794
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Seres Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-273794) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on August 15, 2023 or as soon as practicable thereafter.
* * * *
The Company requests that we be notified of such effectiveness by a telephone call to Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540 and that such effectiveness also be confirmed in writing.
Very truly yours,
Seres Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Seres Therapeutics, Inc. 200 Sidney Street – 4th Floor Cambridge, MA 02139 August 11, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed August 8, 2023 File No. 333-273794 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Seres Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-273794) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on August 15, 2023 or as soon as practicable thereafter. * * * * The Company requests that we be notified of such effectiveness by a telephone call to Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540 and that such effectiveness also be confirmed in writing. Very truly yours, Seres Therapeutics, Inc. By: /s/ David Arkowitz David Arkowitz Executive Vice President, Chief Financial Officer and Head of Business Development cc: Jennifer A. Yoon, Latham & Watkins LLP